October 19, 2023
The U.S. Department of Health and Human Services (HHS) announced on October 13 that HHS and Pfizer have reached an agreement that will transition Paxlovid, the COVID-19 therapeutic, to the commercial market.
Preparations for the transition will begin next month, but Paxlovid will remain available for ordering from HHS through December 15.
Individuals on Medicare and Medicaid will access free government-procured Paxlovid through a patient assistance program through the end of 2024. Individuals who are uninsured or underinsured will access free government-procured Paxlovid through a patient assistance program through the end of 2028.
Pfizer will operate a copay assistance program for those with private insurance through 2028. Pfizer has agreed to replenish any government-procured product that is about to expire with up-to-date product and has also agreed to provide HHS with a stockpile of 1 million treatment courses for future COVID-19 surges.
HHS is working on additional details, particularly about the patient assistance program. Pfizer has not yet announced cost details for Paxlovid, but there is media speculation that the cost will be several times the current government negotiated price of $530/course.
May 29, 2025
As the Legislature works to complete its work on the state’s two-year budget, another deadline is looming. Legislators are required to pass a balanced budget before the end of the fiscal year—June 30, 2025. If they don’t meet that deadline, the state will begin a partial shutdown.
May 29, 2025
Registration has opened for the Empowering Physicians: A Night of Reflection and Engagement event, featuring best-selling author Elisabeth Rosenthal, MD.
May 29, 2025
The AMA is encouraging physicians to contact their U.S. senators and urge them to revise the reconciliation bill passed recently by the U.S. House of Representatives. While the bill includes language that would stabilize Medicare physician payments, it also threatens to cripple Medicaid and CHIP.